Deciphering the molecular profile of plaques, memory decline and neuron loss in two mouse models for Alzheimer's disease by deep sequencing.

PubWeight™: 0.83‹?›

🔗 View Article (PMC 3997018)

Published in Front Aging Neurosci on April 16, 2014

Authors

Yvonne Bouter1, Tim Kacprowski2, Robert Weissmann3, Katharina Dietrich1, Henning Borgers1, Andreas Brauß1, Christian Sperling3, Oliver Wirths1, Mario Albrecht4, Lars R Jensen3, Andreas W Kuss3, Thomas A Bayer1

Author Affiliations

1: Division of Molecular Psychiatry, Georg-August-University Goettingen, University Medicine Goettingen , Goettingen , Germany.
2: Department of Bioinformatics, Institute of Biometrics and Medical Informatics, University Medicine Greifswald , Greifswald , Germany ; Department of Functional Genomics, Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald , Greifswald , Germany.
3: Human Molecular Genetics, Department for Human Genetics of the Institute for Genetics and Functional Genomics, Institute for Human Genetics, University Medicine Greifswald, Ernst-Moritz-Arndt University Greifswald , Greifswald , Germany.
4: Department of Bioinformatics, Institute of Biometrics and Medical Informatics, University Medicine Greifswald , Greifswald , Germany ; Institute for Knowledge Discovery, Graz University of Technology , Graz , Austria.

Articles cited by this

(truncated to the top 100)

Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet (2000) 336.52

Differential expression analysis for sequence count data. Genome Biol (2010) 64.56

RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet (2009) 58.77

The transcriptional landscape of the yeast genome defined by RNA sequencing. Science (2008) 48.99

A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome. Science (2008) 29.99

Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res (2002) 28.38

Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol (2007) 17.69

Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods (1984) 16.43

Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A (1985) 16.10

Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15

Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet (2009) 14.86

Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 12.56

Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behav Neurosci (1992) 11.73

Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol (1999) 10.45

Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet (2013) 9.46

Alzheimer's disease. Lancet (2006) 9.15

Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet (2012) 8.55

Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol (1999) 7.69

Most "dark matter" transcripts are associated with known genes. PLoS Biol (2010) 6.60

Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA (2000) 6.55

Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci (2006) 6.52

Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci (1991) 5.71

Kinesin superfamily motor proteins and intracellular transport. Nat Rev Mol Cell Biol (2009) 5.61

Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A (2003) 5.44

2012 Alzheimer's disease facts and figures. Alzheimers Dement (2012) 5.43

The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci (2012) 4.92

Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci (1998) 4.19

GC-content normalization for RNA-Seq data. BMC Bioinformatics (2011) 3.89

Doublecortin expression levels in adult brain reflect neurogenesis. Eur J Neurosci (2005) 3.79

Increased hippocampal neurogenesis in Alzheimer's disease. Proc Natl Acad Sci U S A (2003) 3.52

Molecular motors in neurons: transport mechanisms and roles in brain function, development, and disease. Neuron (2010) 3.49

The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol (1998) 3.45

Multiple epigenetic maintenance factors implicated by the loss of Mll2 in mouse development. Development (2006) 3.28

A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature (2001) 3.28

Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem (1999) 3.20

Cdk5 is essential for synaptic vesicle endocytosis. Nat Cell Biol (2003) 3.11

Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int (2002) 3.10

Defining the transcriptome and proteome in three functionally different human cell lines. Mol Syst Biol (2010) 3.00

Amyloid beta-protein assembly and Alzheimer disease. J Biol Chem (2008) 2.90

Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci U S A (1992) 2.84

Whole transcriptome sequencing reveals gene expression and splicing differences in brain regions affected by Alzheimer's disease. PLoS One (2011) 2.80

Resolving controversies on the path to Alzheimer's therapeutics. Nat Med (2011) 2.78

The cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation. Genes Dev (1996) 2.59

Disruption of neurogenesis by amyloid beta-peptide, and perturbed neural progenitor cell homeostasis, in models of Alzheimer's disease. J Neurochem (2002) 2.45

Differences between vascular and plaque core amyloid in Alzheimer's disease. J Neurochem (1988) 2.24

Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am J Pathol (2004) 2.15

Replication of CLU, CR1, and PICALM associations with alzheimer disease. Arch Neurol (2010) 2.02

Ubiquilin interacts with ubiquitylated proteins and proteasome through its ubiquitin-associated and ubiquitin-like domains. FEBS Lett (2004) 1.91

Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch Biochem Biophys (1993) 1.90

Cdk5 deregulation in the pathogenesis of Alzheimer's disease. Trends Mol Med (2004) 1.76

Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice. J Neurosci (2003) 1.76

A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics (2003) 1.68

A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide--the first step of a fatal cascade. J Neurochem (2004) 1.68

Brain amyloid-β oligomers in ageing and Alzheimer's disease. Brain (2013) 1.64

Disruption of neurogenesis in the subventricular zone of adult mice, and in human cortical neuronal precursor cells in culture, by amyloid beta-peptide: implications for the pathogenesis of Alzheimer's disease. Neuromolecular Med (2002) 1.63

Progressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins. FEBS J (2010) 1.58

Gene expression and cellular content of cathepsin D in Alzheimer's disease brain: evidence for early up-regulation of the endosomal-lysosomal system. Neuron (1995) 1.58

Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. Am J Pathol (2004) 1.56

Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. J Neurosci (2002) 1.51

Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Aβ aggregation in the 5XFAD mouse model of Alzheimer's disease. Neurobiol Aging (2010) 1.46

Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. Acta Neuropathol (2010) 1.46

Dorsal hippocampus and classical fear conditioning to tone and context in rats: effects of local NMDA-receptor blockade and stimulation. Hippocampus (2003) 1.35

Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer's disease. Brain (2010) 1.35

Target identification for CNS diseases by transcriptional profiling. Neuropsychopharmacology (2008) 1.32

The role of metallobiology and amyloid-β peptides in Alzheimer's disease. J Neurochem (2011) 1.31

Neuronal nitric-oxide synthase localization mediated by a ternary complex with synapsin and CAPON. Proc Natl Acad Sci U S A (2002) 1.27

Intraneuronal beta-amyloid accumulation in the amygdala enhances fear and anxiety in Alzheimer's disease transgenic mice. Biol Psychiatry (2009) 1.25

Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms. Neurochem Int (2006) 1.24

Anti-Aβ drug screening platform using human iPS cell-derived neurons for the treatment of Alzheimer's disease. PLoS One (2011) 1.23

Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer disease. J Biol Chem (2011) 1.23

Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer's disease. Exp Neurol (1998) 1.21

Complement activation by neurofibrillary tangles in Alzheimer's disease. Neurosci Lett (2001) 1.20

Transient intraneuronal A beta rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice. Acta Neuropathol (2008) 1.16

Neuronal clearance of amyloid-β by endocytic receptor LRP1. J Neurosci (2013) 1.13

Comparative analysis of cortical gene expression in mouse models of Alzheimer's disease. Neurobiol Aging (2005) 1.12

Expression in brain of amyloid precursor protein mutated in the alpha-secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice. EMBO J (1996) 1.11

The structure of the human synapsin I gene and protein. J Biol Chem (1990) 1.11

It may take inflammation, phosphorylation and ubiquitination to 'tangle' in Alzheimer's disease. Neurodegener Dis (2006) 1.10

Mature astrocytes in the adult human neocortex express the early neuronal marker doublecortin. Brain (2007) 1.09

Failures to reconsolidate memory in a mouse model of Alzheimer's disease. Neurobiol Learn Mem (2009) 1.08

The detection of microRNA associated with Alzheimer's disease in biological fluids using next-generation sequencing technologies. Front Genet (2013) 1.08

Deregulated Cdk5 activity is involved in inducing Alzheimer's disease. Arch Med Res (2012) 1.08

Motor protein KIF1A is essential for hippocampal synaptogenesis and learning enhancement in an enriched environment. Neuron (2012) 1.07

Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers. PLoS One (2011) 1.07

Intracellular Aß triggers neuron loss in the cholinergic system of the APP/PS1KI mouse model of Alzheimer's disease. Neurobiol Aging (2008) 1.06

General and dramatic glial reaction in Alzheimer brains. Neurology (1990) 1.06

Neprilysin and insulin-degrading enzyme levels are increased in Alzheimer disease in relation to disease severity. J Neuropathol Exp Neurol (2009) 1.05

The role of clusterin in Alzheimer's disease: pathways, pathogenesis, and therapy. Mol Neurobiol (2012) 1.05

N-truncated amyloid β (Aβ) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits. Acta Neuropathol (2013) 1.03

A serial analysis of gene expression profile of the Alzheimer's disease Tg2576 mouse model. Neurotox Res (2009) 1.03

Transcriptome profiling in neurodegenerative disease. J Neurosci Methods (2010) 1.02

Expression of VGF mRNA in the adult rat central nervous system. J Comp Neurol (1998) 1.02

Histone-methyltransferase MLL2 (KMT2B) is required for memory formation in mice. J Neurosci (2013) 1.01

APP/PS1KI bigenic mice develop early synaptic deficits and hippocampus atrophy. Acta Neuropathol (2009) 1.01

Genetic cathepsin B deficiency reduces beta-amyloid in transgenic mice expressing human wild-type amyloid precursor protein. Biochem Biophys Res Commun (2009) 1.00

Intraneuronal Aβ accumulation and neurodegeneration: lessons from transgenic models. Life Sci (2012) 1.00

A PPARdelta agonist reduces amyloid burden and brain inflammation in a transgenic mouse model of Alzheimer's disease. Curr Alzheimer Res (2009) 0.99

Transthyretin and the brain re-visited: is neuronal synthesis of transthyretin protective in Alzheimer's disease? Mol Neurodegener (2011) 0.99

Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease. J Biol Chem (2012) 0.99

Regional alteration of synapsin I in the hippocampal formation of Alzheimer's disease patients. Acta Neuropathol (2003) 0.98